

P. Limousin-Dowsey
P. Pollak
N. Van Blercom
P. Krack
A. Benazzouz
A.-L. Benabid

Thalamic, subthalamic nucleus and internal pallidum stimulation in Parkinson's disease

Abstract The limits of drug therapy in severe forms of Parkinson's disease

P. Limousin-Dowsey (✉)
MRC Human Movement and Balance Unit
Institute of Neurology
23 Queen Square
London WC1N3BG
email: P.Limousin@ion.ucl.ac.uk

P. Limousin-Dowsey · P. Pollak
N. Van Blercom · P. Krack · A. Benazzouz
A.-L. Benabid
Neurosciences Department
Unité INSERM 318
CHU de Grenoble, BP 217X
38043 Grenoble, France

P. Krack
Neurology Department
University of Kiel, Germany

have lead to a renewal of functional neurosurgery of the basal ganglia and the thalamus. Deep brain stimulation (DBS) of these structures was developed with the aims of reducing the morbidity of surgery and of offering an adaptative treatment. DBS was first applied to the thalamus in patients with severe tremor. Tremor of the hemibody is greatly reduced by stimulation of the contralateral electrode in 85 % of the cases. There is little change in other symptoms. However, motor fluctuations and dyskinesias are a more frequent problem than severe tremor; in attempt to treat these symptoms, DBS has recently been applied to the subthalamic nucleus (STN) and the inter-

nal pallidum (GPI). STN stimulation greatly decreases off motor symptoms and motor fluctuations, which allows a reduction of drug dosage and consequently of dyskinesias. GPI stimulation decreases dyskinesias in most patients, but the effect on off motor symptoms is more variable from one series to another, from very good to nil. The severe morbidity of DBS applied to these 3 targets is low. Comparative studies of the cost and the efficacy of DBS and lesions applied to these different targets are now required.

Key words Parkinson's disease · Deep brain stimulation · Subthalamic nucleus · Internal pallidum · Thalamus

Introduction

Levodopa preparations are very effective in treating patients with Parkinson's disease. But after several years of treatment some patients develop motor fluctuations and dyskinesias difficult to control by adapting their drugs. As a consequence there has been a renewal of functional neurosurgery in the past ten years. The surgical approach to the basal ganglia presently benefits from new technologies to locate the target like MRI, easier access to electrophysiology, and new forms of treatment like chronic deep brain stimulation (DBS). DBS can be presently applied to three different targets: the ventrointermediate nucleus of the thalamus (Vim), the subthalamic nucleus (STN) and the internal pallidum (GPI).

Surgical procedure

The main steps of the surgical procedures are common to all three targets. The target is located using different methods which can be combined: imaging (ventriculography, MRI and CT) and electrophysiology (micro or semi-microrecordings and electrical stimulation). The electrode is implanted in stereotaxic conditions, under local anaesthesia, so the effect of electrical stimulation on parkinsonian features and adverse effects can be assessed. Subsequently the electrode is connected to a pulse generator implanted in the subclavicular area, usually under general anaesthesia. The electrode for chronic stimulation (Medtronic 3387, or 3389, Minneapolis, USA) includes 4 contacts at its' tip. One or several contacts can

be selected as a cathode. The voltage, the frequency and the pulse width delivered by the pulse generator can be adjusted.

Ventrolateral nucleus of the thalamus stimulation

Vim stimulation is proposed as an alternative to thalamotomy since 1987 [5]. Initially it was implanted contralaterally to a thalamotomy to reduce the risk of the bilateral procedure. Subsequently bilateral stimulations were implanted with the aim to reduce morbidity. No comparative study between thalamic stimulation and thalamotomy is available yet, but one is in progress in the Netherlands [30].

Many reports show a good effect and a low rate of severe morbidity of thalamic stimulation [1, 6, 11–13, 16–18, 25]. A multicenter study published recently including 73 parkinsonian patients, 16 implanted bilaterally, shows that the stimulation of 85 % of the electrodes allows a good reduction of tremor at 12 months follow-up [25]. Both upper and lower limb tremor were reduced. Limb akinesia and rigidity were slightly reduced, but there was no effect on speech, postural stability and gait. Activities of daily living were as a consequence improved. Out of 110 patients implanted (including patients with essential tremor), side effects related to surgery included 3 subdural hematomas and 1 thalamic hematoma which resolved, 2 infections of the system which required the system to be temporarily removed, 2 subcutaneous hematomas, 1 attention-cognitive deficit, 7 mild dysarthria, 3 mild disequilibrium and 1 dystonia. The electrode was replaced in 5 patients because of loss of efficacy probably related to displacement. At 12 months follow-up the average voltage was 2.5 V, pulse width 81.9 ms and rate 162.9 Hz. There were only slight changes in medications.

Subthalamic nucleus stimulation

STN stimulation is based on studies done in the monkey model of Parkinson's disease [2, 3, 7–10, 15, 26, 34]. In these monkeys, an overactivity of the STN is found and lesions or electrical stimulation improve parkinsonian features [2, 3, 7–10, 15, 26, 34]. Therefore, STN stimulation was applied to patients with idiopathic Parkinson's disease [27]. Different studies have confirmed its efficacy [22–24, 28]. A study of 20 patients with at least one-year follow-up shows an average improvement of 60 % of off motor symptoms [24]. Akinesia, rigidity, tremor, dystonia, gait, freezing and postural stability can be improved. As a consequence motor fluctuations disappeared and activities of daily living were greatly improved.

Levodopa induced dyskinesias are reduced over time, probably because levodopa dosage is reduced by 50 % in average. In the short term, STN stimulation can induce dyskinesias if electrical parameters are increased over a threshold. In the total group of 24 patients the following adverse effects were encountered: one severe bleeding, 1 extracerebral infection, 1 cognitive deficit, 8 transient confusion and 5 eyelid opening apraxia.

The average voltage at 12 months was 2.5 V, the frequency was 130 Hz and the pulse width 60 μ s, patients were stimulated continuously. Patients with a good response to levodopa before surgery respond better to surgery [19].

Internal pallidum stimulation

GPi stimulation is proposed as an alternative to pallidotomy, with the aim to reduce the morbidity. There is no comparative study available between the two procedures. GPi stimulation greatly decreases levodopa induced dyskinesias in most studies [4, 14, 20, 29, 31–33]. The effect on off-symptoms varies between studies from none to important [4, 14, 20, 29, 31–33]. This discrepancy is probably related to the complexity of the connections within GPi. Two studies show very different effects of GPi stimulation according to the topography of the stimulated contact [4, 20]. Dyskinesias and akinesia can be improved or worsened, depending on whether the dorsal or the ventral GPi is stimulated. There is no proper comparative study between GPi and STN stimulation. A retrospective study in two small groups of patient is more in favor of STN because it allows a better effect on off-phase and a decrease in levodopa dosage [21].

Conclusions

DBS of Vim, GPi and STN can improve various aspects of idiopathic Parkinson's disease. However, patients with other parkinsonian syndromes, or with cognitive deficits or general disease should not be operated. Vim stimulation is effective only against tremor and should be proposed to patients disabled only by tremor. The question of an alternative target, like STN, should be raised, particularly in young patients, who might develop other symptoms. STN stimulation is very effective for patients with fluctuations and allows indirect reduction of dyskinesias. The main effect of GPi stimulation is against dyskinesias; other symptoms are variably improved. We now need comparative studies of the cost and benefit of these different surgical procedures.

References

1. Alesch F, Pinter MM, Hetscher RJ, Fertl L, Benabid AL, Koos WT (1995) Stimulation of the ventral intermediate thalamic nucleus in tremor dominated Parkinson's disease and essential tremor. *Acta Neurochir* 136: 75–81
2. Aziz TZ, Peggs D, Sambrook MA, Crossman AR (1991) Lesion of the subthalamic nucleus for the alleviation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced parkinsonism in the primate. *Mov Disord* 6: 288–293
3. Aziz TZ, Peggs D, Argarwal E, Sambrook MA, Crossman AR (1992) Subthalamic nucleotomy alleviates parkinsonism in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed primates. *Br J Neurosurg* 6: 575–582
4. Bejjani B, Damier P, Arnulf I, Bonnet AM, Vidailhet M, Dormont D, Pidoux B, Cornu P, Marsault C, Agid Y (1997) Pallidal stimulation for Parkinson's disease. Two targets? *Neurology* 49: 1564–1569
5. Benabid AL, Pollak P, Louveau A, Henry S, de Rougemont J (1987) Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease. *Appl Neurophysiol* 50: 344–346
6. Benabid AL, Pollak P, Gervason C, Hoffmann D, Gao DM, Hommel M, Perret JE, de Rougemont J (1991) Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus. *Lancet* 337: 403–406
7. Benazzouz A, Gross C, Feger J, Boraud T, Bioulac B (1993) Reversal of rigidity and improvement in motor performance by subthalamic high-frequency stimulation in MPTP-treated monkeys. *Eur J Neurosci* 5: 382–389
8. Benazzouz A, Boraud T, Féger J, Burbaud P, Bioulac B, Gross C (1996) Alleviation of experimental hemiparkinsonism by high-frequency stimulation of the subthalamic nucleus in primates: a comparison with levodopa treatment. *Mov Disord* 11: 627–632
9. Bergman H, Wichmann T, DeLong MR (1990) Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. *Science* 249: 1436–1438
10. Bergman H, Wichmann T, Karmon B, DeLong MR (1994) The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of Parkinson's disease. *J Neurophysiol* 72: 507–520
11. Blond S, Siegfried J (1991) Thalamic stimulation for the treatment of tremor and other movement disorders. *Acta Neurochir* 52: 109–111
12. Blond S, Caparros Lefebvre D, Parker F, Assaker R, Petit H, Guieu JD, Christiaens JL (1992) Control of tremor and involuntary movement disorders by chronic stereotactic stimulation of the ventral intermediate thalamic nucleus. *J Neurosurg* 77: 62–68
13. Caparros Lefebvre D, Blond S, Vermersch P, Pecheux N, Guieu JD, Petit H (1993) Chronic thalamic stimulation improves tremor and levodopa induced dyskinesias in Parkinson's disease. *J Neurol Neurosurg Psychiatry* 56: 268–273
14. Ghika J, Villemure JG, Fankhauser H, Favre J, Assal G, Ghika-Schmid F (1998) Efficiency and safety of bilateral contemporaneous pallidal stimulation (deep brain stimulation) in levodopa-responsive patients with Parkinson's disease with severe motor fluctuations: a 2-year follow-up review. *J Neurosurg* 89: 713–718
15. Guridi J, Herrero M, Luquin M, Guillen J, Ruberg M, Laguna J, Vila M, Javoy-Agud F, Agud Y, Hirsch E, Obeso JA (1996) Subthalamicotomy in parkinsonian monkeys. Behavioural and biochemical analysis. *Brain* 119: 1717–1727
16. Hariz GM, Bergenheim AT, Hariz MI, Lindberg M (1998) Assessment of ability/disability in patients treated with chronic thalamic stimulation for tremor. *Mov Disord* 13: 78–83
17. Koller W, Hristova A (1996) Efficacy and safety of stereotaxic surgical treatment of tremor disorders. *European Journal of Neurology* 3: 507–514
18. Koller W, Pahwa R, Busenbark K, Hubble J, Wilkinson S, Lang A, Tuite P, Sime E, Lazano A, Hauser R, Malapira T, Smith D, Tarsy D, Miyawaki E, Norregaard T, Kormos T, Olanow CW (1997) High-frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor. *Ann Neurol* 42: 292–299
19. Krack P, Limousin P, Pollak P, Benazzouz A, Koudsie A, Benabid AL (1998) The preoperative response to an acute L-dopa-test predicts the outcome of subthalamic nucleus stimulation in Parkinson's disease. *Mov Disord* 13, suppl 2: 296
20. Krack P, Pollak P, Limousin P, Hoffmann D, Benazzouz A, Benabid AL (1998) Inhibition of levodopa effects by internal pallidal stimulation. *Mov Disord* 13: 648–652
21. Krack P, Pollak P, Limousin P, Hoffmann D, Xie J, Benazzouz A, Benabid AL (1998) Subthalamic nucleus or internal pallidal stimulation in young onset Parkinson's disease. *Brain* 121: 451–457
22. Kumar R, Lozano AM, Kim J, Hutchison WD, Sime E, Hallett E, Lang AE (1998) Double-blind evaluation of subthalamic nucleus deep brain stimulation in advanced Parkinson's disease. *Neurology* 51: 850–855
23. Limousin P, Pollak P, A Benazzouz, Hoffmann D, Le Bas JF, Broussolle E, Perret JE, Benabid AL (1995) Effect on parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. *Lancet* 345: 91–95
24. Limousin P, Krack P, Pollak P, Benazzouz A, Ardouin C, Hoffmann D, Benabid AL (1998) Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. *N Engl J Med* 339: 1105–1111
25. Limousin P, Speelman JD, Gielen F, Janssens M (1999) Multicenter European study of thalamic stimulation in parkinsonian and essential tremor. *J Neurol Neurosurg Psychiatry* 66: 289–296
26. Miller WC, DeLong MR (1987) Altered tonic activity of neurons in the globus pallidus and subthalamic nucleus in the primate MPTP model of parkinsonism. In: Carpenter MB and Jayaraman A (ed) *The Basal Ganglia II*. Plenum, New York, pp 415–427
27. Pollak P, Benabid AL, Gross C, Gao DM, Laurent A, Benazzouz A, Hoffmann D, Gentil M, Perret J (1993) Effets de la stimulation du noyau sous-thalamique dans la maladie de Parkinson. *Rev Neurol* 149: 175–176
28. Rodriguez Oroz MC, Guridi J, Alvarez L, Mewes K, Macias R, Vitek J, DeLong MR, Obeso JA (1998) The subthalamic nucleus and tremor in Parkinson's disease. *Mov Disord* 13, suppl 3: 111–118
29. Siegfried J, Lippitz B (1994) Bilateral chronic electrostimulation of ventro-posterolateral pallidum: a new therapeutic approach for alleviating all parkinsonian symptoms. *Neurosurgery* 35: 1126–1129

-
30. Speelman JD, Schuurman PR, Bosch DA (1998) Thalamic stimulation versus thalamotomy in a prospective randomized trial. *Mov Disord* 13, suppl 2: 200
 31. Tronnier VM, Fogel W, Kronenbueger M, Krause M, Steinvorth S (1997) Is the medial globus pallidus a site for stimulation or lesioning in the treatment of Parkinson's disease? *Stereotact Funct Neurosurg* 69: 62–68
 32. Tronnier VM, Fogel W, Kronenbueger M, Steinvorth S (1997) Pallidal stimulation: an alternative to pallidotomy? *J Neurosurg* 87: 700–5
 33. Volkmann J, Sturm V, Weiss P, Kappler J, Voges J, Koulousakis A, Lehrke R, Hefter H, Freund HJ (1998) Bilateral high-frequency stimulation of the internal globus pallidus in advanced Parkinson's disease. *Ann Neurol* 44: 953–61
 34. Wichmann T, Bergman H, DeLong MR (1994) The primate subthalamic nucleus. III-Changes in motor behavior and neuronal activity in the internal pallidum induced by subthalamic inactivation in the MPTP model of parkinsonism. *J Neurophysiol* 72: 521–530